Some researchers took advantage of tumor-produced IL-8 in order to guide the IL-8 receptor (CXCR1 or CXCR2)-expressing CAR-T cells to infiltrate solid tumors (glioblastoma, hepatocellular carcinoma (HCC), ovarian and pancreatic cancer), and stimulate an antitumor immune response. This evidence concerns the gene CXCR1 and neoplasm.